There have been many surprise developments and, unfortunately, multiple league-altering injuries in the early stages of the 2025 NFL season, thus, affecting next year’s draft. As such, our predicted ...

FedEx Corp (NYSE:FDX) delivered its financial results for the first quarter of fiscal 2026 on Thursday after the bell. Here’s a look at the key details from the report. FDX stock is racing ahead of ...

GameSpot may get a commission from retail offers. During Gamescom Opening Night Live, Wargaming unveiled World of Tanks 2.0, a massive update to the 15-year-old free-to-play tank battle game, which ...

OpenAI just dropped its first open-weight models in over five years. The two language models, gpt-oss-120b and gpt-oss-20b, can run locally on consumer devices and be fine-tuned for specific purposes.

Philippine housing unit prices saw an increase in the first quarter of 2025, albeit at a slower pace, driven by higher prices in the National Capital Region (NCR), the Bangko Sentral ng Pilipinas (BSP ...

GameSpot may get a commission from retail offers. After some delays, 7 Days To Die is finally launching the big 2.0 Storm's Brewing update on June 30. Storm's Brewing adds deadly elemental effects and ...

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109, United States ...

After spending the week in Buffalo, N.Y., at the NHL Scouting Combine, here’s my second version of a first-round mock for the 2025 NHL Draft. These are my best predictions for the first 32 picks after ...

*Note: One patient in each cohort finished treatment without at least one post-baseline tumor assessment. Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the ...

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Participants had ...

Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343. 10-year follow up of a phase 2 clinical trial ...